Camurus AB (publ) (0RD1.L)

479,67 -16,11 (-3,25%) Al cierre: 05:36PM BST

Camurus AB (publ)

Ideon Science Park
Lund 223 70
Sweden
46 4 62 86 57 30
https://www.camurus.com

Sector(es): 
Sector: 
Empleados a tiempo completo: 213

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Fredrik Tiberg	President, CEO, CSO & Director	12,06M	N/A	1963
Mr. Jon U. Garay Alonso	Chief Financial Officer	N/A	N/A	1973
Mr. Torsten Malmstrom	Chief Technology Officer	N/A	N/A	1968
Mr. Rein Piir B.Sc.	Vice President of Investor Relations	N/A	N/A	1958
Ms. Maria Lundqvist	Global Head of Human Resources	N/A	N/A	1966
Mr. Markus Johnsson	Senior Vice President of R&D	N/A	N/A	1972
Mr. Fredrik Joabsson	Chief Business Development Officer	N/A	N/A	1972
Mr. Richard Jameson	Chief Commercial Officer	N/A	N/A	1964
Mr. Alberto M. Pedroncelli	Chief Medical Officer	N/A	N/A	1964

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en SEK.

Descripción

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden. The company operates as a subsidiary of Sandberg Development AB.

Gobierno corporativo

El ISS Governance QualityScore de Camurus AB (publ), a día 1 de mayo de 2024, es 4. Las puntuaciones base son Auditoría: 8; Tablero: 6; Derechos de los accionistas: 1; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.